Broad leukemia subtype evidence map
Table 1 consolidates findings across CML, AML, APL, CLL, and ALL, including study type, experimental model, intervention, and reported result.
↳ Table 1, pages 13–14
Abstract
NF-E2-related factor 2 (Nrf2) transcription factor has contradictory roles in cancer, which can act as a tumor suppressor or a proto-oncogene in different cell conditions (depending on the cell type and the conditions of the cell environment). Nrf2 pathway regulates several cellular processes, including signaling, energy metabolism, autophagy, inflammation, redox homeostasis, and antioxidant regulation. As a result, it plays a crucial role in cell survival. Conversely, Nrf2 protects cancerous cells from apoptosis and increases proliferation, angiogenesis, and metastasis. It promotes resistance to chemotherapy and radiotherapy in various solid tumors and hematological malignancies, so we want to elucidate the role of Nrf2 in cancer and the positive point of its targeting. Also, in the past few years, many studies have shown that Nrf2 protects cancer cells, especially leukemic cells, from the effects of chemotherapeutic drugs. The present paper summarizes these studies to scrutinize whether targeting Nrf2 combined with chemotherapy would be a therapeutic approach for leukemia treatment. Also, we discussed how Nrf2 and NF-κB work together to control the cellular redox pathway. The role of these two factors in inflammation (antagonistic) and leukemia (synergistic) is also summarized.
Key Claims
Primary findingSupported
Nrf2 protects cancerous cells from apoptosis and increases proliferation, angiogenesis, and metastasis. It promotes resistance to chemotherapy and radiotherapy in various solid tumors and hematological malignancies
multiple preclinical leukemia studies support chemoresistance, but the narrative selection method and cross-cancer context limit certainty
Abstract
SecondarySupported
Nrf2 and NF-κB work together to control the cellular redox pathway; antagonistic in inflammation, synergistic in leukemia
cited mechanistic studies support pathway interaction, though the unsystematic narrative synthesis limits confidence in its generality
Abstract; Nrf2 and inflammation subsection
SecondaryUnsupported
Nrf2 is a poor prognostic marker in leukemia
the review does not present commensurate clinical prognostic evidence in leukemia
Conclusion
SecondaryTentative
Inhibition of Nrf2, whether by knockdown techniques, siRNA, or the use of inhibitory compounds, combined with current frontline therapies, stops cell growth and causes apoptosis in malignant cells
individual preclinical studies support growth inhibition and apoptosis, but broad generalization beyond tested models remains uncertain
Conclusion
Derived from the full evaluation — not a separate score.
Strengths · Limitations
Strengths
Useful pathway interaction framework
The manuscript uses Nrf2–NF-κB interactions to connect redox regulation, inflammation, leukemia progression, and treatment resistance.
↳ Nrf2 and inflammation subsection; Figures 2 and 4
Logical molecular-to-disease organization
The review proceeds from Nrf2 structure and regulation through biological functions and then leukemia-specific evidence, making a long technical discussion navigable.
↳ Nrf2 structure through leukemia subtype sections
Limitations
Conflicting evidence receives little analysis
The AML section acknowledges studies in which Nrf2 activation may be beneficial but does not compare their mechanisms or implications with the dominant inhibition narrative.
↳ Nrf2 and Acute myeloid leukemia subsection, page 16
No literature selection method reported
No databases, search dates, search terms, or inclusion criteria are reported, leaving the completeness and balance of the literature selection uncertain.
↳ Entire manuscript; no review methods section
Conclusions outrun preclinical evidence base
The Conclusion labels Nrf2 a poor prognostic marker and presents inhibition as promising despite limited clinical evidence and acknowledged context-dependent effects.
↳ Conclusion; Nrf2 function subsection, pages 6–7
Nabu Commentary
Table 1 and the subtype sections provide a broad map of preclinical Nrf2 findings across major leukemia categories. The structure is clear, but the article mainly catalogs individual studies rather than critically comparing their designs, heterogeneity, and boundary conditions. The absence of a source-selection method and the limited treatment of contrary AML findings reduce confidence in the balance of the synthesis. Consequently, claims about prognosis and therapeutic targeting require stronger qualification than the Abstract and Conclusion provide.
Author Note / Field Feedback
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Dimension breakdown
Study Quality
Limited2.6
Contribution
2.5
The review provides a useful leukemia-specific compilation and an Nrf2–NF-κB organizing frame, but its advance is primarily descriptive. The claim that Nrf2 is a poor prognostic marker in leukemia exceeds the clinical prognostic evidence described in the review.
Conclusion; Table 1; Nrf2 in leukemia subsection
“Nrf2 is a poor prognostic marker in leukemia”
Methodological Rigour
2.4
The subtype structure and study-level descriptions make the literature easy to survey, but the synthesis largely proceeds study by study. Conflicting AML findings receive little analysis, and no search or selection procedure explains how the literature was assembled.
Nrf2 and Acute myeloid leukemia subsection, page 16; entire manuscript
“However, a few conflicting studies suggest that increasing Nrf2 expression is influential in treating AML.”
Reporting
3.0
Headings and progression from molecular biology to leukemia subtypes make the review followable. Some Abstract and Conclusion statements are more definitive than the predominantly preclinical and context-dependent evidence warrants.
Abstract; Nrf2 function subsection, pages 6–7; Conclusion
“targeting Nrf2 combined with chemotherapy would be a therapeutic approach for leukemia treatment”
Positioning
2.8
The manuscript cites a broad Nrf2 literature and explicitly recognizes its tumor-suppressive and oncogenic roles. It does not trace acknowledged contrary AML findings through to the certainty of its concluding therapeutic recommendation.
Nrf2 function subsection, pages 6–7; Nrf2 and Acute myeloid leukemia subsection, page 16; Conclusion
“Therefore, more investigation is needed to clarify the role of Nrf2 in AML.”
Reliability
Caveats4 of 4 checks
Internal CoherenceNoted
The narrative is structurally coherent and contains no primary-data inconsistencies, but central wording in the Abstract and Conclusion is more definitive than the preclinical and context-dependent synthesis supports.
Research ConductClean
Ethics, consent, and data availability are appropriately marked not applicable for a narrative review, and no original-data or image-integrity issue was identified. A competing-interests statement was not visible in the supplied text, which is an assessability gap rather than evidence of misconduct.
Flags: 1 declared / 5 total
Reference IntegrityClean
217 of 218 checkable references verified
221 references in manuscript 3 have no canonical index record — counted, but not index-checkable 1 reference confirmed by manual review
Post-Publication RecordClean
No retraction notice found in Retraction Watch.
Last checked: 18 Aug 2026
Sources: Retraction Watch ✓
Impact Potential
Low2.5
Relevance
2.7
Chemotherapy resistance in leukemia is a recognized problem, and the review identifies Nrf2 inhibition and several candidate compounds as possible responses. It does not identify specific clinical decision-makers, trials, or implementation settings.
Introduction; CML and AML subsections; Conclusion
“More targeted and effective inhibitors and more mechanistic research are required”
Readiness
2.2
The reviewed evidence consists mainly of cell-line experiments with occasional animal or embryo models. No leukemia clinical trial or deployment-ready Nrf2 intervention is presented.
Table 1; CML and AML subsections
“Type of study”
Generalizability
2.2
Coverage across CML, AML, APL, CLL, and ALL gives breadth within leukemia. Transfer to patients remains uncertain because most findings arise from particular cell lines and heterogeneity is not systematically assessed.
Table 1; leukemia subtype subsections
“Nrf2 in leukemia”
Trajectory
2.7
The review connects multiple subtype-specific studies and candidate inhibitors to an established preclinical research program. Its descriptive synthesis and unresolved dual-role problem limit its value as a framework for cumulative clinical development.
Table 1; Pros and cons of the available strategies for targeting Nrf2; Conclusion
“finding new Nrf2/ARE inhibitors with the right potency, specificity, and safety is still a significant challenge”
AI-generated, human-governed. Something look off? Contact us to request a review.